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Abstract  
 
Background: Obesity is considered a multifactorial disease that has importantly increased the development of chronic 
degenerative diseases. Drugs available for treating obesity have the inconvenience of producing side effects of importance. 
In Mexican traditional medicine, the seeds of Thevetia peruviana have been widely employed for weight reduction.  
Materials and Methods: The effect produced by different extracts of T. peruviana on MonoSodium Glutamate (MSG)-
induced obesity in mice was evaluated. A chemical analysis oriented toward the identification of the chemical compounds 
contained in the active extract was carried out.  
Results: Oral administration of the hexanic extract of T. peruviana (for 7 weeks) was capable of diminishing weight gain 
by up to 24.1% in the mice without observing the development of resistance to insulin. Median lethal dose of the hexanic 
and Ethyl Acetate (EtOAc) extracts was >2 g/kg. By utilizing bio-assay guided fractionation, eight secondary metabolites 
were purified and characterized. 
Conclusion: The hexanic extract obtained from Thevetia peruviana seeds was capable of reducing weight gain in mice 
with induced obesity. In addition, this extract showed good response to the glucose tolerance test, was able to avoid the 
development of insulin resistance, and also substantially increased serum adiponectin levels. Eight low-polarity compounds 
were identified in the active fraction. This species could be considered for ongoing investigation as a potential option to 
reduce obesity 
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Abbreviations: MSG, MonoSodium Glutamate; EtOAc, Ethyl Acetate; TLC, Thin-Layer Chromatography; BW, Body 
Weight; CNS, Central Nervous System; T2D, Type 2 Diabetes; ELISA, Enzyme-Linked ImmunoSorbent Assay; r.o., retro-
orbitally; BMI, Body Mass Index; UPLC, Ultra Performance Liquid Chromatography; LD50, median Lethal Dose.  
 
Introduction 
 
Nearly two decades ago (1997), obesity was declared a worldwide epidemic by the World Health Organization 
(WHO) (Dávila-Torres et al. 2015). It is considered a chronic disease that has as its main characteristic the increase of 
adipose tissue, which is manifested in Body Weight (BW) gain. The relationship between a person’s weight and height is 
used to determine the degree of obesity (Barbany and Foz 2002). 
Obesity is the result of the loss of equilibrium between the ingestion of food with a high-energy content and 
energetic expenditure (Rankinen and Bouchard 2008); 95% of patients with obesity have exogenous or simple obesity 
(International Obesity Task Force [IOFT] 2012). Thus, with the aim of diminishing obesity, the main strategies have been 
primarily based on lifestyle modification (Waxman 2004). In obesity, the increase of adipose tissue, which releases 
excessive amounts of free fatty acids and hormones, produces insulin resistance and promotes glucose release in liver. This 
tissue also produces glycerol and proinflammatory cytokines; the release of these compounds produces hyperglycemia,  
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hyperinsulinemia, hypercholesterolemia, and hypertriglyceridemia (Kopelman 2000; Stumvoll and Goldstein van Haeften 
2008). 
For the treatment of obesity, there are drugs, among which are included appetite suppressants, which act by 
modulating the Central Nervous System (CNS), and drugs that modulate the absorption of specific nutrients such as fat, 
both with the inconvenience of producing important side effects (Luque and Rey 1999; Heck et al. 2000). Among the uses 
of medicinal plants in traditional medicines, it is possible to find species that are employed for “weight loss” and, among 
the compounds contained by some of these plants, flavonoids, alkaloids, and saponins have been identified. These 
compounds usually produce antiobesity effects throughout different mechanisms of action (Yun 2010). 
In an individual with obesity, the organism can generate insulin resistance that, in turn, can comprise a factor that 
allows the development of Type 2 Diabetes (T2D), a disease related with different disorders such as hyperlipidemia, 
atherosclerosis, and hypertension (Stumvoll and Goldstein van Haeften 2008). 
MonoSodium Glutamate (MSG) is the sodium salt of the amino acid known as glutamic acid. This salt is obtained 
via the fermentation of sugar cane or from cereals (Arteaga-Sánchez 2012) and it is utilized as a condiment to potentiate 
food flavors; thus, it is a basic element in the food industry. Administration of MSG in early life stages, as in the case of 
neonatal mice, affects the development of the CNS and has repercussions, including that of affecting the satiety threshold, 
in this manner stimulating the appetite and increasing food consumption (Carbonero-Carreño 2013). Different studies 
conducted on mice and rats have proposed the relationship between the consumption of this compound and obesity 
(Arteaga-Sánchez 2012). Subcutaneous (s.c.) administration of MSG in neonatal mice induces obesity. Obesity is a 
multifactorial disease that has importantly increased the development of chronic-degenerative diseases, thus medical-care 
costs.  
Due to the dramatic increase in the prevalence of obesity and T2D worldwide, it is urgent to promote novel 
strategies for combating the epidemiologic growth of these diseases; for this, the consideration of the potential of certain 
medicinal plants would be advantageous (Zaid et al. 2015). Recent publications highlight the potential that natural bioactive 
products possess in the prevention of chronic diseases such as cancer, cardiovascular diseases, and metabolic and 
inflammatory disorders and, in addition, their probable impact on obesity and insulin resistance (Huang et al. 2016). In an 
ethnobotanical study, it was identified that a total of 139 plant species native to Mexico, Central America, and the 
Caribbean are utilized empirically for the treatment of obesity. Thirty three of these species have been included in some 
scientific work, but 106 of these, to our knowledge, have not yet been evaluated (Alonso-Castro et al. 2015).  
Among plants included in scientific reports, we can mention the following: Momordica charantia; Centella 
asiatica; Morinda citrifolia; Annona muricata (Gooda et al. 2012); Camellia sinensis; Caralluma fimbriata; Citrus 
aurantium; Coleus forskohlii; Garcinia cambogia; Phaseolus vulgaris (Astell et al. 2013); Zingiber officinale; Caralluma 
fimbriata, and Hibiscus sabdariffa (Hasani-Ranjabar et al. 2009). 
The seeds from Thevetia peruviana (Pers.) K. Schum. of the Apocynaceae family, popularly known as “Codo de 
fraile” and “Ayoyote” (Argueta et al. 1994), are utilized in Mexican traditional medicine for weight reduction (Torres 
2009). Other scientific works have identified antidiarrheic, antimicrobial, and cytotoxic properties (Hassan et al. 2011), 
while pesticide activity has been identified in T. peruviana bark and leaves (Singh et al. 2010). 
The objective of the present work was to evaluate the effect produced by different extracts of T. peruviana in mice 
with MSG-induced obesity and, by means of bio-assay guided fractionation, to identify the chemical compounds contained 
in the active extract. Since adiponectin (produced exclusively by the adipose tissue) possesses anti-inflammatory and 
insulin-sensitizing effects (Messinis et al. 2013), and because resistin has been implicated in the pathogenesis of insulin 
resistance and T2D (Kusminski et al. 2005), both proteins were quantified in the plasma of mice at the end of treatment 
administration.     
  
Materials and Methods 
Plant material  
 
Plant material of Thevetia peruviana (Pers.) K. Schum., of the Apocynaceae Family, was obtained (January 2015) 
in its natural habitat in the state of Morelos, Mexico. A herbarium sample was prepared for its identification and deposited 
for reference at the IMSSM Herbarium of the Mexican Institute of Social Security. Abigail Aguilar-Contreras, M.Sc., 
Herbarium Director, was charged with the identification of the plant species. The voucher sample was registered with the 
number IMSSM-16000. Seeds were extracted from the endocarp, crushed until obtaining a 2-mm particle size, and dried 
under dark conditions at room temperature. 
 
Extract preparation  
 
The dried and ground material (seeds, 2.76 kg) was extracted by sub-sequential maceration in the ascending 
polarity solvents n-hexane and Ethyl Acetate (EtOAc). The liquid extracts (10 L) were filtered and processed to total 
dryness by means of a rotary evaporator (Laborota 4000, Heidolph). These extracts, which included n-hexane (1.10 kg, 
39.8%) and EtOAc (169.3 g, 6.12%), were stored at –20°C and protected from light. 
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Chemical separation of the Thevetia peruviana active extract  
 
Based on the results obtained from the evaluation of the whole extracts, the n-hexane extract was subjected to 
bioassay-guided fractionation. The first chemical separation was performed by chromatographic open column previously 
packed with silica gel 60 employing a mixture of n-hexane/Ethyl Acetate (EtOAc) gradient system as mobile phase 
(starting with 100% of n-hexane and progressively increasing  EtOAc until reaching 100% of the last solvent). Samples of 
200 mL were taken and analyzed by Thin-Layer Chromatography (TLC). This chemical monitoring process allowed for the 
grouping of fractions according to their composition, obtaining a total of eight fractions: C1F1–C1F8.  
The most active fraction (C1F2) was subjected to a chromatographic open column previously packed with 100 g of silica 
gel 60. The n-hexane/EtOAc gradient system was used as mobile phase, starting with 100% of the solvent of least polarity 
and finalizing with 100% EtOAc. One hundred eighty samples were obtained, which were grouped into five final fractions 
according to their chemical composition (C2F1–C2F5).  
 
GC-MS analysis 
 
The chemical composition of C2F1, C2F2, and C2F3 fractions was analyzed by gas chromatography in a 
chromatograph equipped with a quadrupole mass detector in electron impact mode at 70 eV. Volatile compounds were 
separated on an HP 5-ms capillary column (25 m long, 0.2 mm i.d., 0.3-µm film thickness). Furnace temperature was set at 
40°C for 2 min, then programmed from 40–260°C at 10°C/min, and maintained for 20 min at 260°C. Mass detector 
conditions were as follows: interphase temperature 200°C, and mass acquisition range, 20–550. Injector and detector 
temperatures were set at 250°C and 280°C, respectively. The splitless injection mode was carried out with 1 µL of each 
fraction (3 mg/mL solution). The carrier gas was helium at a 1-mL/min flow rate. Identification of volatiles was performed, 
comparing their mass spectra with those of the National Institute of Standards and Technology (NIST) 1.7 Library.  
 
Evaluation of acute toxicology  
 
To evaluate possible toxic effects, different doses (50, 100, 500, 1,000, and 2,000 mg/kg) of the hexanic and 
EtOAc extracts from T. peruviana seeds were administered orally (o.a.) to CD-1 mice (average weight, 41.0 g). Survival 
was measured during a 24-h period. 
 
Material utilized for pharmacological experiments 
 
We employed MSG (Aldrich, ≥98% pure) as obesity inducer. In order to quantify the concentrations of plasma 
resistin and adiponectin, kits including Enzyme-Linked Immunosorbent Assay (ELISA) (the Mouse adiponectin/Acrp30 
kit) and the Mouse Resistin Quantikine kit (R&D Systems) were employed, while for glucose measurement, we used an 
AccuChek Performa Roche® Glucometer. Finally, for measurement of cholesterol and triglycerides, we utilized an 
Accutrend Performa Roche® Glucometer. 
 
Obesity induction with MSG in mice 
 
Male and female CD-1-strain mice were paired. Offspring obtained from the pairings were utilized in the 
experimentation as follows: on postnatal days 2 and 4, mice received 2 mg/kg of MSG subcutaneously (s.c.), while on 
postnatal days 6, 8, and 10, they were administered 4 mg/kg of MSG via the same route. 
Once obese mice were obtained (at 2 months of age and with an average weight of 31 g), the animals were 
organized into four groups (with eight animals each) and administered daily for 7 weeks with treatments via oral route 
(through an orogastric [o.g.] cannula) as follows: the negative control group was treated with the vehicle (Tween 80) alone; 
the positive control group received Orlistat (10 mg/kg) plus vehicle; the first experimental group was treated with the 
hexanic extract of T. peruviana (50 mg/kg) plus vehicle, and the second experimental group, with the EtOAc extract of T. 
peruviana (50 mg/kg) plus vehicle. With the aim of obtaining a reference (no obese animals), a witness group was included 
(also composed of eight animals), which did not receive treatment with MSG.     
The BW of the mice was measured weekly and, at the end of treatment, blood levels of cholesterol, triglycerides, 
adiponectin, and resistin were measured. In addition, a glucose tolerance test was performed, as well as an insulin resistance 
test.  
The studies were carried out under Official Mexican Regulations for the Correct Use of Animal Experimentation 
(Norma Oficial Mexicana, http://www.fmvz.unam.mx/fmvz/principal/archivos/062ZOO.pdf) and conducted in accordance 
with internationally accepted principles for laboratory animal use and care (e.g., European Community guidelines/EEC 
Directive of 1986 or US guidelines/NIH publication).  
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Glucose tolerance test  
 
At the end of week 7 of administration and after a 12-h fasting period, we measured the plasma glucose level, in all 
experimental groups, and the result was considered as time zero. Later, we administered a 2-g/kg dose of glucose 
intraperitoneally (i.p.). For construction of the glucose tolerance curve, determinations of glycemia in caudal vein were 
performed at 15, 30, 60, and 120 min.  
 
Insulin resistance test 
 
At the end of week 7 of administration and without a previous fasting period, in all experimental groups, we 
administered a 0.75-International Unit (IU)/kg dose of insulin i.p. For construction of the insulin resistance curve, we 
carried out measurements of glycemia in caudal vein at 0, 15, 30, 60, and 120 min.  
 
Determination of resistin and adiponectin  
 
For quantification of resistin and adiponectin in plasma, at the end of week 7 of treatment administration, we 
selected four mice from each group for resistin and four for adiponectin determination. 
We obtained blood samples retro-orbitally (r.o.) with previously heparinized capillary tubes (in Eppendorf tubes), which 
were centrifuged in order to obtain the plasma samples. In both cases, the manufacturer’s instructions (of the ELISA kits) 
were followed.  
 
Determination of body mass index and visceral fat 
 
At the end of the administration period, we determined the Body Mass Index (BMI) in all of the animals. This was 
obtained by means of dividing the weight of the mouse in g by the length of the same mouse (defined as the length between 
the nose and anus in cm of the mouse). For measurement of visceral fat, the animals were sacrificed, the visceral fat was 
dissected, and, in all cases, with the aid of a standardized filter paper, the weight of the tissue was determined.      
 
Statistical analysis 
 
For statistical analysis, we employed the IBM SPSS ver. 20. statistical software program. To identify the 
difference between groups, we utilized ANalysis Of VAriance (ANOVA) and the Tukey post-hoc test. A statistically 
significant difference was considered between groups when p values were <0.05.  
 
Results 
Evaluation of Acute Toxicology 
 
Evaluation of the different extracts of T. peruviana (doses of 0.05–2 g/kg orally [o.a.]) demonstrated that the LD50 
of the hexanic and EtOAc extracts was >2 g/kg. 
 
Effect Produced by the Extracts of Thevetia peruviana on Mice with Induced Obesity 
 
In the MSG-induced obesity model, animals included in the witness, in the positive control, and in the negative 
control groups presented a progressive increase of BW during the 7 treatment weeks; however, as can be appreciated in 
Figure 1, the weight increase in obese animals that received the vehicle (negative control) was significantly greater. On the 
other hand, the extracts obtained from T. peruviana were capable of significantly reducing BW gain, especially in the group 
treated with the hexanic extract, which demonstrated minimal weight increase during the 7 treatment weeks. In this group, 
weight gain was 24.1% lower in comparison with that of the negative control group. From week 2 of administration, a 
statistically significant difference was identified (p = 0.047) between the group treated with the hexanic extract of T. 
peruviana and the group that received the vehicle (negative control). This difference was also identified in the remaining 
experimental group from week 3 of administration (p = 0.047 and p = 0.001). 
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Figure 1: Effect produced by oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicle (negative control), 
and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana in mice with MonoSodium 
Glutamate (MSG)-induced obesity. Witness group was not treated with MSG. * = p <0.05 with regard to the negative 
control in the Tukey test. 
 
Glucose Tolerance Test  
 
Once the administration period of the treatments concluded (at 7 weeks), four animals from each group were 
selected randomly in order to perform a glucose tolerance test. We were able to observe that, in animals with obesity, the 
group that received the vehicle alone (negative control) was the only group that presented high rates of glycemia at time 
zero (>200 mg/dL) and, after 2 h of having been administered glucose, this same group again presented high rates of 
glycemia (Figure 2). The animals treated with the extracts of T. peruviana demonstrated an expected response to the 
glucose challenge and recovered the amounts of the glycemic baseline, evidencing the absence of glucose intolerance.  
                   
Figure 2: Glucose tolerance test carried out at the end of week 7 of treatment with the hexanic and Ethyl Acetate (EtOAc) 
extracts (50 mg/kg) of the seeds of Thevetia peruviana, Orlistat (positive control), and vehicle (negative control) in mice 
with MonoSodium Glutamate (MSG)-induced obesity. Witness group was not treated with MSG.  
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Insulin Resistance Test 
 
Once the administration period was concluded (7 weeks), four animals of each group were selected randomly to 
perform an insulin resistance test. In this case, the animals were not submitted to a previous fast. At baseline time, a blood 
glucose concentration was identified within normal rates (for animals not submitted to a fast) in the group treated with the 
hexanic extract and in the group treated with Orlistat, as well as in the witness group. Negative-control-group animals and 
those of the experimental group treated with the EtOAc extract did not respond to the administration of insulin, evidencing 
a possible development of insulin resistance. In contrast, the witness group, the positive control group, and the group that 
received treatment with the hexanic extract of T. peruviana exhibited an expected response to administration of insulin, 
suggesting that sensitivity to insulin was preserved in these groups (Figure 3).     
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Insulin resistance test performed at the end of week 7 of treatment with the hexanic and Ethyl Acetate (EtOAc) 
extracts (50 mg/kg) of the seeds of Thevetia peruviana, Orlistat (positive control), and vehicle (negative control) in mice 
with MonoSodium Glutamate (MSG)-induced obesity. Witness group was not treated with MSG.  
 
 
Effect Produced by Thevetia peruviana on the Plasma Levels of Cholesterol, Triglycerides, and Body Mass Index 
 
At the end of the period of treatment administration (7 weeks), the blood cholesterol level was determined in all 
animals with caudal-vein blood. The greatest concentration of cholesterol was observed in the group treated with the 
vehicle (negative control), whose result was significantly (p = 0.006) higher than that of the witness group. The extracts of 
T. peruviana and Orlistat (positive control) lowered blood cholesterol levels, but the only group that achieved a significant 
difference (p = 0.013), and levels very similar to those of the witness group, was that administered the hexanic extract of T. 
peruviana (Figure 4).   
In these same animals, we determined blood triglyceride levels. In all of the treatment groups, higher levels were 
observed than those exhibited by the witness group. Only the group of animals treated with the hexanic extract of T. 
peruviana evidenced a lower level of triglycerides (Figure 5), but without reaching a statistically significant difference.    
Evaluation of BMI at the end of treatment administration permitted identifying that administration of MSG 
induced a considerable increase of this variable, which can be appreciated in the group administered the vehicle alone 
(negative control). Statistical analysis reflected a significant difference (p = 0.001) of this group of mice with regard to the 
witness group. In this case, the hexanic extract of T. peruviana achieved lowest BMI values and exhibited a significant 
difference (p = 0.003) with respect to the negative control, but did not reach the levels presented by the witness group. The 
groups of animals that received Orlistat (positive control) and the EtOAc extract of T. peruviana also demonstrated a lower 
BMI than the group treated with vehicle alone (Figure 6).    
MSG administration substantially increased visceral fat in the mice. This effect could not have been inhibited by 
the administration (during 7 weeks) of Orlistat (positive control), nor by administration of the extracts of T. peruviana (data 
not shown).  
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Figure 4: Effect produced by the oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicle (negative 
control), and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana on plasma cholesterol 
levels in mice with MonoSodium Glutamate (MSG)-induced obesity. ** = p <0.05 with regard to the negative control 
group (Vehicle) in the Tukey test. b = p <0.05 with respect to the witness group in the Tukey test. Witness group was not 
treated with MSG. 
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Figure 5: Effect produced by the oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicule (negative 
control), and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana on the blood triglyceride 
levels in mice with MonoSodium Glutamate (MSG)-induced obesity. Witness group was not treated with MSG. 
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Figure 6: Effect produced by the oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicle (negative 
control), and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana on Body Mass Index (BMI) 
in mice with MonoSodium Glutamate (MGS)-induced obesity. Witness group was not treated with MSG. ** = p <0.05 with 
relation to the negative control group (Vehicle) in the Tukey test. b = p <0.05 with respect to the witness group in the 
Tukey test. 
 
Effect Produced by Thevetia peruviana on Resistin and Adiponectin Levels 
 
At the end of the administration period, animals were selected randomly to take blood samples for measurement of 
resistin and adiponectin plasma concentrations. Resistin levels were very similar in the different treatment groups; only 
animals treated with Orlistat alone (positive control) presented high levels of this cytosine (Figure 7). In the case of 
adiponectin, all of the animals treated with the plant extracts and Orlistat exhibited higher concentrations, while the hexanic 
extract of T. peruviana was that which presented the highest concentration of this cytosine (Figure 8).  
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Figure 7:  Effect produced by the oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicule (negative 
control), and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana on blood resistin levels in 
mice with MonoSodium Glutamate (MSG)-induced obesity. Witness group was not treated with MSG. ** = p <0.05 with 
regard to the negative control group (Vehicle) in the Tukey test.  
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Figure 8: Effect produced by the oral administration (o.a.) of 10 mg/kg of Orlistat (positive control), vehicle (negative 
control), and the hexanic and Ethyl Acetate (EtOAc) extracts (50 mg/kg) of Thevetia peruviana in blood adiponectin levels 
in mice with MonoSodium Glutamate (MSG)-induced obesity. Witness group was not treated with MSG. ** = p <0.05 
regarding the relationship with the negative control group (Vehicle) in the Tukey test.  
 
Bio-assay Guided Purification and Structural Elucidation of Active Compounds 
 
By means of gravitational open column chromatography followed by Gas Chromatography-Mass Spectrometry 
(GC-MS) analysis, identification was possible of the following non-polar compounds classified as sterols: stigmasta-3,5-
dien-7-one (1); stigmasta-4-en-3-one (2); stigmasta-5,24(28)-dien-3ol (3); 24-methylenecycloartan-3-one (4); stigmasta-
5,22-dien-3ol (5); 13,27-cycloursane (6); 7-dehydrodiosgenin (7); β-sitosterol (8), and campesterol (9) (Figure 9). 
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Figure 9: Chemical structure of compounds identified in the active fraction of Thevetia peruviana. 
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Discussion 
 
The hexanic and EtOAc extracts obtained from T. peruviana seeds, that were administered orally during 7 weeks, 
reduced weight gain in the mice, especially the hexanic extract, which maintained an even lower weight than that 
demonstrated by the group treated with Orlistat (positive control). The inhibition of weight gain achieved by the hexanic 
extract of T. peruviana was 24.1%. Another aspect-of-interest was that observed in the group of mice treated with the 
hexanic extract, which demonstrated a lower fasting glycemic level, adequate response to the glucose tolerance test, and the 
extract was capable of avoiding the development of insulin resistance. Additionally, the levels of blood cholesterol and 
triglycerides exhibited by this group of animals were similar to that of the witness group and lower than those of the group 
treated with vehicle alone. The plasma adiponectin concentration in these animals was considerably higher to that found in 
the positive control group and in the group receiving vehicle alone (negative control). This datum merits special 
importance, due to that adiponectin is a hormone deriving from the adipocyte, whose reduction has been identified as a 
factor associated with T2D, coronary disease, hypertension, and ventricular hypertrophy, while adiponectin has been 
identified as a molecule-of-importance for preventing obesity-related diseases (López-Jaramillo 2016). 
The results found in this work are comparable with those that have been identified in other species with significant 
effects on obesity: for example, for the species Psacalium decompositum, intragastric (i.g.) administration of 150 mg/kg 
(during 2 weeks) of a fructooligosaccharides fraction, obtained from the roots of this plant, achieved diminution of BW, 
cholesterol, and triglycerides, accompanied by associated anti-inflammatory effect (Merino-Aguilar et al. 2014). In an 
international scenario, it is probable that the plant species Garcinia cambogia is that which is most frequently referred in 
the scientific literature due to its potential effect against obesity. This species has demonstrated the capacity to reduce 
visceral fat and adipocyte size, in addition to being capable of reducing glucose intolerance and resistin levels in the plasma 
of mice fed with a fat-rich diet (Kim et al. 2013). Administration of a crude extract of saponins obtained from Korean Red 
Ginseng (200 mg/kg, i.p.) during 3 weeks achieved a reduction of up to 20% of weight in rats fed a diet high in fat (Kim et 
al. 2005). A recent review article cited that an interesting number of plant species have shown their effect on BW in animal 
models. Among these species, the following are noteworthy: Camelia sinensis; the administration of an aqueous extract 
(0.8, 1.6, and 3.2 g/L) in Wistar rats fed a diet rich in fat during 26 weeks attenuated visceral accumulation of fat in 40%; 
Hibiscus sabdariffa; the aqueous extract of the calyx, administered (120 mg/kg/day) during 60 days, diminished weight 
gain by up to 22%, and Persea americana; the administration of an aqueous and methanolic extract (10 mg/kg) during 8 
weeks in hypercholesteremic rats produced a 25% reduction in BW gain in comparison with the control (Gamboa-Gómez et 
al. 2015).  
By means of bio-assay guided fractionation, it was possible to isolate and identify different compounds in the 
active fraction; the majority of these corresponded to the phytosterol group. The latter is especially important because 
phytosterols have been considered very interesting chemical compounds due to their potential health benefits. Increased 
attention has been generated because they promote cardiovascular health, due to their hypocholesterolemic properties. 
These compounds are found in cell membranes and are structurally in close proximity to cholesterol. Stigmasta-5,22-dien-
3-ol and β-sitosterol are the main phytosterol constituents of Coxilachrymal-jobi L., a crop widely used in traditional 
Chinese Medicine (Wu TT et al. 2007). This plant species, popularly known as Adlay, demonstrated the ability to inhibit 
adipocyte differentiation and to increase glucose uptake in 3T3-L1 cells (Ha do et al. 2010). The water extract from this 
plant has demonstrated anti-obesity effects through a neuroendocrine action mechanism (Kim et al. 2007) 
The phytosterol compounds, stigmasta-3,5-dien-7-one, stigmasta 4-en-3-one, and β-sitosterol have also been 
identified in the plant species Capsella bursa-pastoris, a plant widely utilized in traditional medicine as an anti-
inflammatory in many countries (Al-Snafi 2015). 
Stigmasta-3,5-dien7-one and sitosterol were found in the extract of the fruits and leaves of Vaccinium myrtillus L., 
a plant native to Europe, North Asia, Western Canada, and the U.S., which is the most frequent ingredient of commercial 
antidiabetic products available on the market in the 20th century (Mohammed et al. 2015).  
β-sitosterol has been found in the Caralluma fimbriata extract, which is employed as an anti-obesity agent and appetite 
suppressor (Dutt et al. 2012).   
Bio-assay guided separation permitted the isolation and identification of stigmasta-4-en-3-one as the active 
compound from Parkia speciosa with a hypoglycemic effect (Jamaluddin 1995). 
Daily administration of β-sitosterol at a dose of 25 mg for a prolonged time in patients was able to reduce serum total 
cholesterol with a reduction of serum total lipids (Best et al. 1955).  
 
Conclusion 
 
With the results obtained, it can be concluded that the hexanic extract from Thevetia peruviana seeds was capable 
of reducing weight gain (up to 24.1%) in mice with MSG-induced obesity. In addition, this extract showed good response 
to the glucose tolerance test, was able to avoid the development of insulin resistance, and also substantially increased serum 
adiponectin levels. The chemical separation procedure allowed for the identification of the following active chemical 
compounds: stigmasta-3,5-dien-7-one, stigmasta-4-en-3-one; stigmasta-5,22-dien-3-one; stigmasta-5,24(28)-dien-3ol; 24- 
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methylenecycloartan-3-one; stigmasta-5,22-dien-3ol; 13,27-cycloursane; 7-dehydrodiosgenin; β-sitosterol, and 3,27-
cycloursane. This species could be considered for ongoing investigation as a potential option to reduce obesity. 
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